OSI Pharmaceuticals(美國(guó))

OSI Pharmaceuticals

美國(guó)OSIPharmaceuticalswww.osip.comOSIPharmaceuticalsInc.致力于通過(guò)發(fā)現(xiàn)、開(kāi)發(fā)和銷售高質(zhì)量、創(chuàng)新和差異化的靶向治療藥物，延長(zhǎng)癌癥和糖尿病、肥胖癥患者的生命并改善患者的生活質(zhì)量，實(shí)現(xiàn)“調(diào)整藥物和改善生活”的目的。OSIPharmaceuticals是的生物科技企業(yè)，主要研究、開(kāi)發(fā)和銷售高質(zhì)量藥品，延長(zhǎng)全球癌癥和糖尿病患者的生命 或改善其生活質(zhì)量。2010年日藥商Astellas40億美元收購(gòu)美生物技術(shù)公司OSI armaceuticalsiscommittedto“shapingmedicineandchanginglives”bydiscovering,developingandcommercializinghigh-quality,novelanddifferentiatedpersonalizedmedicinesdesignedtoextendlifeandimprovethequalityoflifeforpatientswithcanceranddiabetes/obesity.Wespecializeinthediscoveryanddevelopmentofinnovativemoleculartargetedtherapiesthataddresssignificantunmetmedicalneeds,andstrivetoturnpioneeringscienceintobreakthroughtherapiesforpatientssufferingfromlife-threateningdiseases.OurOncologybusinessisanchoredbyourflagshipproduct,Tarceva®(erlotinib),asmallmolecul